Saturday, June 14, 2025
  • Business
  • Investing
  • World-news
  • Stock
No Result
View All Result
Finance Mastery News
Advertisement
  • Business
  • Investing
  • World-news
  • Stock
No Result
View All Result
Finance Mastery News
No Result
View All Result
Home Investing

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

admin by admin
May 15, 2025
in Investing
0
Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.

HIGHLIGHTS

  • Key milestone achieved, with 15 confirmed responses recorded in the ongoing Phase 1b/2a ACCENT trial
  • Sufficient confirmed responses have now been recorded to demonstrate that narmafotinib combined with chemotherapy is superior to chemotherapy alone.
  • The ACCENT trial is evaluating narmafotinib in combination with the chemotherapies gemcitabine and Abraxane® in patients with advanced pancreatic cancer
  • Narmafotinib is a highly potent and selective FAK inhibitor discovered at the Melbourne-based Cooperative Research Centre for Cancer Therapeutics.
  • Phase 2a ACCENT trial is fully recruited with top-line data expected in mid Q3 2025

A confirmed partial response is a formal designation of response where tumour shrinkage >30% is recorded and sustained for two (2) or more months and where no new cancerous lesions have been detected. As pancreatic cancer is highly aggressive it is extremely rare for patients to achieve a complete response (CR).

The ACCENT trial is an open-label study meaning that all patients on the study receive narmafotinib in combination with the standard-of-care therapy. The data obtained in this trial is compared to historical data for the combination of gemcitabine and Abraxane in pancreatic cancer, and specifically data from the MPACT study, upon which we have closely modelled our trial1.

At the outset of the study a statistical analysis was performed which identified that a patient cohort of 50 patients would be sufficient to allow the efficacy of our combination to be ascertained with reasonable confidence if 15 or more responders (confirmed PR or CR) were recorded. A total of 55 advanced pancreatic patients have enrolled in the study since January 2024, with 21 patients still on study at this time.

As noted in our recent press release2, the drug continues to be well tolerated by patients with the rate and type of adverse events for the narmafotinib combination being similar to that reported for chemotherapy alone.

Amplia CEO and MD Dr Chris Burns commented: “We are extremely excited to have now recorded 15 confirmed partial responses in the ACCENT trial, demonstrating the benefit of adding narmafotinib to standard-of-care chemotherapy. With over 20 patients still on study we are hopeful that further PR’s will be observed”

Click here for the full ASX Release

This post appeared first on investingnews.com

Previous Post

EL2780 Award – New Targets from Airborne MT

Next Post

Multiple Uranium Anomalies Identified at Key NT Projects

admin

admin

Next Post
Multiple Uranium Anomalies Identified at Key NT Projects

Multiple Uranium Anomalies Identified at Key NT Projects

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    • Trending
    • Comments
    • Latest
    Criminals are looting millions from ATMs in Europe. Here’s why Germany is a prime target

    Criminals are looting millions from ATMs in Europe. Here’s why Germany is a prime target

    October 28, 2024
    Israeli MP behind bill to expel key UN agency accuses US of interfering with process

    Israeli MP behind bill to expel key UN agency accuses US of interfering with process

    October 28, 2024
    British nurse Lucy Letby loses bid to appeal single attempted murder conviction

    British nurse Lucy Letby loses bid to appeal single attempted murder conviction

    October 25, 2024
    North Korean troops spotted in Russian border region with Ukraine, says Kyiv

    North Korean troops spotted in Russian border region with Ukraine, says Kyiv

    October 25, 2024
    Anguished Air India crash families give DNA samples to help identify loved ones

    Anguished Air India crash families give DNA samples to help identify loved ones

    0
    Private payroll growth slowed to 122,000 in July, less than expected, ADP says

    Private payroll growth slowed to 122,000 in July, less than expected, ADP says

    0
    The 10 worst states to retire in the U.S. No. 1 isn’t California or New York

    The 10 worst states to retire in the U.S. No. 1 isn’t California or New York

    0
    Boeing taps aerospace veteran Ortberg to replace Dave Calhoun as CEO

    Boeing taps aerospace veteran Ortberg to replace Dave Calhoun as CEO

    0
    Anguished Air India crash families give DNA samples to help identify loved ones

    Anguished Air India crash families give DNA samples to help identify loved ones

    June 14, 2025
    Italian teenager Carlo Acutis to become first millennial saint on September 7

    Italian teenager Carlo Acutis to become first millennial saint on September 7

    June 14, 2025
    A weakened Iran has few options for striking back after Israel’s devastating blows

    A weakened Iran has few options for striking back after Israel’s devastating blows

    June 14, 2025
    An Israeli operation hit Iran’s nuclear program and killed top military officials. Here’s what we know

    An Israeli operation hit Iran’s nuclear program and killed top military officials. Here’s what we know

    June 14, 2025

    Recent News

    Anguished Air India crash families give DNA samples to help identify loved ones

    Anguished Air India crash families give DNA samples to help identify loved ones

    June 14, 2025
    Italian teenager Carlo Acutis to become first millennial saint on September 7

    Italian teenager Carlo Acutis to become first millennial saint on September 7

    June 14, 2025
    A weakened Iran has few options for striking back after Israel’s devastating blows

    A weakened Iran has few options for striking back after Israel’s devastating blows

    June 14, 2025
    An Israeli operation hit Iran’s nuclear program and killed top military officials. Here’s what we know

    An Israeli operation hit Iran’s nuclear program and killed top military officials. Here’s what we know

    June 14, 2025

    Disclaimer: financemasterynews.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Browse by Category

    • Business
    • Investing
    • Stock
    • World-news

    Recent News

    Anguished Air India crash families give DNA samples to help identify loved ones

    Anguished Air India crash families give DNA samples to help identify loved ones

    June 14, 2025
    Italian teenager Carlo Acutis to become first millennial saint on September 7

    Italian teenager Carlo Acutis to become first millennial saint on September 7

    June 14, 2025
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 financemasterynews.com | All Rights Reserved

    No Result
    View All Result

    Copyright © 2025 financemasterynews.com | All Rights Reserved